| Regulation of transforming growth factor-β1–driven lung fibrosis by galectin-3 AC MacKinnon, MA Gibbons, SL Farnworth, H Leffler, UJ Nilsson, ... American journal of respiratory and critical care medicine 185 (5), 537-546, 2012 | 577 | 2012 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, H McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 511 | 2021 |
| Ly6Chi Monocytes Direct Alternatively Activated Profibrotic Macrophage Regulation of Lung Fibrosis MA Gibbons, AC MacKinnon, P Ramachandran, K Dhaliwal, R Duffin, ... American journal of respiratory and critical care medicine 184 (5), 569-581, 2011 | 481 | 2011 |
| Respiratory follow-up of patients with COVID-19 pneumonia PM George, SL Barratt, R Condliffe, SR Desai, A Devaraj, I Forrest, ... Thorax 75 (11), 1009-1016, 2020 | 438 | 2020 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 318 | 2022 |
| Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial JAZ Jankowski, J De Caestecker, SB Love, G Reilly, P Watson, S Sanders, ... The Lancet 392 (10145), 400-408, 2018 | 268 | 2018 |
| Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study TM Drake, AB Docherty, EM Harrison, JK Quint, H Adamali, S Agnew, ... American journal of respiratory and critical care medicine 202 (12), 1656-1665, 2020 | 224 | 2020 |
| Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis N Hirani, AC MacKinnon, L Nicol, P Ford, H Schambye, A Pedersen, ... European Respiratory Journal 57 (5), 2021 | 157 | 2021 |
| Monocytes control second-phase neutrophil emigration in established lipopolysaccharide-induced murine lung injury K Dhaliwal, E Scholefield, D Ferenbach, M Gibbons, R Duffin, ... American journal of respiratory and critical care medicine 186 (6), 514-524, 2012 | 128 | 2012 |
| Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study A Duckworth, MA Gibbons, RJ Allen, H Almond, RN Beaumont, AR Wood, ... The Lancet Respiratory Medicine 9 (3), 285-294, 2021 | 127 | 2021 |
| Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy … TM Maher, VA Tudor, P Saunders, MA Gibbons, SV Fletcher, CP Denton, ... The Lancet Respiratory Medicine 11 (1), 45-54, 2023 | 113 | 2023 |
| Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled … JJ Solomon, SK Danoff, FA Woodhead, S Hurwitz, R Maurer, I Glaspole, ... The Lancet Respiratory Medicine 11 (1), 87-96, 2023 | 95 | 2023 |
| Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study TM Maher, S Stowasser, Y Nishioka, ES White, V Cottin, I Noth, M Selman, ... The Lancet respiratory medicine 7 (9), 771-779, 2019 | 79 | 2019 |
| SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ... EBioMedicine 87, 2023 | 75 | 2023 |
| Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the UKILD post–COVID-19 study I Stewart, J Jacob, PM George, PL Molyneaux, JC Porter, RJ Allen, ... American journal of respiratory and critical care medicine 207 (6), 693-703, 2023 | 73 | 2023 |
| Endobronchial ultrasound-guided fine-needle aspiration and liquid-based thin-layer cytology WAH Wallace, HM Monaghan, DM Salter, MA Gibbons, KM Skwarski Journal of clinical pathology 60 (4), 388-391, 2007 | 57 | 2007 |
| The burden of progressive fibrotic interstitial lung disease across the UK T Simpson, SL Barratt, P Beirne, N Chaudhuri, A Crawshaw, LE Crowley, ... European Respiratory Journal 58 (1), 2021 | 50 | 2021 |
| Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID) JM Wild, JC Porter, PL Molyneaux, PM George, I Stewart, RJ Allen, R Aul, ... BMJ Open Respiratory Research 8 (1), e001049, 2021 | 48 | 2021 |
| TD139, A Novel Inhaled Galectin-3 Inhibitor for The Treatment of Idiopathic Pulmonary Fibrosis (IPF). Results from The First in (IPF) Patients Study. N Hirani, L Nicol, AC MacKinnon, P Ford, H Schambye, Pedersen, ... QJM: An International Journal of Medicine 109 (suppl_1), S16-S16, 2016 | 42 | 2016 |
| Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials TM Maher, P Ford, KK Brown, U Costabel, V Cottin, SK Danoff, ... Jama 329 (18), 1567-1578, 2023 | 39 | 2023 |
